Levetiracetam Stragen

Levetiracetam, the active ingredient in Levetiracetam Stragen, is an antiepileptic presented as an injection solution for intravenous use. It is employed to manage epilepsy, specifically partial‑onset seizures and generalized tonic‑clonic seizures, in patients who require parenteral therapy.

GNH USA supplies Levetiracetam Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to health‑care institutions across multiple regions. Customers benefit from reliable logistics, temperature‑controlled shipping, and comprehensive documentation to facilitate import and clinical use.

Levetiracetam is an antiepileptic drug indicated for seizure disorders.

- Partial‑onset seizures: Reduces seizure frequency in patients with focal onset epilepsy. - Generalized tonic‑clonic seizures: Controls convulsive episodes in generalized epilepsy. - Epilepsy (overall): Provides adjunctive therapy for patients with refractory seizures.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness - Fatigue - Somnolence - Headache

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Stevens‑Johnson syndrome - Suicidal thoughts or behavior

Levetiracetam requires careful clinical monitoring to ensure safe use.

- Monitor renal function: Adjust dosing in patients with impaired clearance. - Adjust dose in renal impairment: Follow renal‑based dosing recommendations. - Avoid abrupt discontinuation: Taper gradually to reduce seizure risk. - Use caution in patients with psychiatric history: Monitor mood changes. - Pregnancy category unknown: Use only if potential benefit justifies risk. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with several concomitant medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: May reduce levetiracetam plasma concentrations. - Valproic acid: May increase levetiracetam levels, requiring monitoring. - Rifampin: May significantly lower levetiracetam exposure.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): Additive sedation. - Alcohol: May enhance central nervous system effects.